Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myocet, Trastuzumab, and Paclitaxel in HER2+ Metastatic Breast Cancer
NCT00294996Phase 3Unknown
- Sponsor
- Sopherion Therapeutics
- Start
- Jan 2006
- Modality
- DNA Intercalators/Alkylators
- Countries
- 11
01
Overview
A Phase 3 trial of doxorubicin liposomal non-pegylated in breast cancer, sponsored by Sopherion Therapeutics. Status: unknown.
02
Drugs
doxorubicin liposomal non-pegylated
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00294996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00294996.